Congratulations to Roger Shi, PhD on his co-author publication in The Journal of Clinical Investigation!

The paper is titled “LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance” by Sijia He, Jiyoon Ryu, Juanhong Liu, Hairong Luo, Ying Lv, Paul R Langlais, Jie Wen, Feng Dong, Zhe Sun, Wenjuan Xia, Jane L Lynch, Ravindranath Duggirala, Bruce J Nicholson, Mengwei Zang, Yuguang Shi, Fang Zhang, Feng Liu, Juli Bai, Lily Q Dong.  Dr. Shi is the Joe R. and Teresa Lozano Long Distinguished Chair in Metabolic Biology and a Professor with the Department of Pharmacology and the Sam and Ann Barshop Institute for Longevity and Aging Studies.

Abstract:

Dysregulation in adipokine biosynthesis and function contributes to obesity-induced metabolic diseases. However, the identities and functions of many of the obesity-induced secretory molecules remain unknown. Here, we report the identification of leucine-rich alpha-2-glycoprotein 1 (LRG1) as an obesity-associated adipokine that exacerbates high fat diet-induced hepatosteatosis and insulin resistance. Serum levels of LRG1 were markedly elevated in obese humans and mice compared with their respective controls. LRG1 deficiency in mice greatly alleviated diet-induced hepatosteatosis, obesity, and insulin resistance. Mechanistically, LRG1 bound with high selectivity to the liver and promoted hepatosteatosis by increasing de novo lipogenesis and suppressing fatty acid β-oxidation. LRG1 also inhibited hepatic insulin signaling by downregulating insulin receptor substrates 1 and 2. Our study identified LRG1 as a key molecule that mediates the crosstalk between adipocytes and hepatocytes in diet-induced hepatosteatosis and insulin resistance. Suppressing LRG1 expression and function may be a promising strategy for the treatment of obesity-related metabolic diseases.

JCI. 2021 Dec 15;131(24):e148545. doi: 10.1172/JCI148545.

Article Categories: News